Evidence map›Paper›PMID 26880249›Full record

ArticleScientific reports2016

IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity.

Yuval Avnir, Corey T Watson, Jacob Glanville, Eric C Peterson, Aimee S Tallarico, Andrew S Bennett, Kun Qin, Ying Fu, Chiung-Yu Huang, John H Beigel and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 132 papers.

0numbers the graph read from it
0cells of the map it votes in
132citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

132 citing papers in PubMed, 211 citations in OpenAlex.

  1. Trial
  2. Protective near-germline antibodies to malaria elicited by RTS,S/AS01bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

72 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Yuval AvnirDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Corey T WatsonDepartment of Biological Sciences, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada.
Jacob GlanvilleProgram in Computational and Systems Immunology, Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California, USA.
Eric C PetersonDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Aimee S TallaricoDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Andrew S BennettDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Kun QinDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Ying FuDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Chiung-Yu HuangDivision of Biostatistics and Bioinformatics Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University 550 N. Broadway, Room 1103-A Baltimore, Maryland 21205-2013, USA.
John H BeigelLeidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702 USA.
Felix BredenDepartment of Biological Sciences, Simon Fraser University, Burnaby, British Columbia, V5A 1S6, Canada.
Quan ZhuDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Wayne A MarascoDepartment of Cancer Immunology &AIDS, Dana-Farber Cancer Institute; Department of Medicine, Harvard Medical School, 450 Brookline Avenue, Boston, Massachusetts 02215, USA.
Dana-Farber Cancer Institute · USFrederick National Laboratory for Cancer Research · USHarvard University · USIcahn School of Medicine at Mount Sinai · USJohns Hopkins University · USSimon Fraser University · CAStanford University · US

Funding

MOLECULAR &CELLULAR IMMUNOBIOLOGYT32AI007290 · NIAID · STANFORD UNIVERSITY · PI Sean Curtis Bendall, Olivia M Martinez · 1985 to 2026
$27.0M
Human Mab Cocktails to Prevent & Treat H5N1 Avian InfluenzaU01AI074518 · NIAID · DANA-FARBER CANCER INST · PI MARASCO, WAYNE A. · 2007 to 2011
$7.2M
Structural Requirements for Broadly Protecting Antibodies to Influenza A & BR56AI109223 · NIAID · DANA-FARBER CANCER INST · PI MARASCO, WAYNE A. · 2014 to 2014
$645k
CCR NIH HHS HHSN261200800001CIntramural NIH HHSNCI NIH HHS HHSN261200800001ENIAID NIH HHS AI074518NIAID NIH HHS AI109223NIAID NIH HHS R56 AI109223NIAID NIH HHS T32 AI007290NIAID NIH HHS U01 AI074518
6 · The paper itself

Abstract

IGHV polymorphism provides a rich source of humoral immune system diversity. One important example is the IGHV1-69 germline gene where the biased use of alleles that encode the critical CDR-H2 Phe54 (F-alleles) to make broadly neutralizing antibodies (HV1-69-sBnAb) to the influenza A hemagglutinin stem domain has been clearly established. However, whether IGHV1-69 polymorphism can also modulate B cell function and Ab repertoire expression through promoter and copy number (CN) variations has not been reported, nor has whether IGHV1-69 allelic distribution is impacted by ethnicity. Here we studied a cohort of NIH H5N1 vaccinees and demonstrate for the first time the influence of IGHV1-69 polymorphism on V-segment usage, somatic hypermutation and B cell expansion that elucidates the dominance of F-alleles in HV1-69-sBnAbs. We provide evidence that Phe54/Leu54 (F/L) polymorphism correlates with shifted repertoire usage of other IGHV germline genes. In addition, we analyzed ethnically diverse individuals within the 1000 genomes project and discovered marked variations in F- and L- genotypes and CN among the various ethnic groups that may impact HV1-69-sBnAb responses. These results have immediate implications for understanding HV1-69-sBnAb responses at the individual and population level and for the design and implementation of "universal" influenza vaccine.

Indexed as

Polymorphism, GeneticAllelesAntibodies, NeutralizingAntibodies, ViralB-LymphocytesGene DosageGene DuplicationGenotypeHumansImmunoglobulin Heavy ChainsInfluenza A virusInfluenza A Virus, H5N1 SubtypeInfluenza VaccinesPolymorphism, Single NucleotideRegulatory Sequences, Nucleic AcidSomatic Hypermutation, ImmunoglobulinAntibodies, NeutralizingAntibodies, ViralImmunoglobulin Heavy ChainsInfluenza Vaccines

Identifiers

PMID26880249
PMCPMC4754645
OpenAlexW2337033889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.